RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
IGM Biosciences Stock

IGM Biosciences Net Income 2024

IGM Biosciences Net Income

-165.37 M USD

Ticker

IGMS

ISIN

US4495851085

WKN

A2PPQK

In 2024, IGM Biosciences's profit amounted to -165.37 M USD, a -32.89% increase from the -246.42 M USD profit recorded in the previous year.

The IGM Biosciences Net Income history

YEARNET INCOME (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

IGM Biosciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into IGM Biosciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by IGM Biosciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects IGM Biosciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of IGM Biosciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into IGM Biosciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing IGM Biosciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on IGM Biosciences’s growth potential.

IGM Biosciences Revenue, EBIT and net profit per share

DateIGM Biosciences RevenueIGM Biosciences EBITIGM Biosciences Net Income
2029e555.47 M undefined0 undefined-99.33 M undefined
2028e359.36 M undefined-41.89 M undefined-160.13 M undefined
2027e224.36 M undefined-133.76 M undefined-161.34 M undefined
2026e51.74 M undefined-243.61 M undefined-164.42 M undefined
2025e10.63 M undefined-241.03 M undefined-190.59 M undefined
2024e46.7 M undefined-185.73 M undefined-165.37 M undefined
20232.13 M undefined-263.46 M undefined-246.42 M undefined
20221.07 M undefined-227.96 M undefined-221.1 M undefined
20210 undefined-165.32 M undefined-165.16 M undefined
20200 undefined-83.28 M undefined-81.36 M undefined
20190 undefined-44.5 M undefined-43.13 M undefined
20180 undefined-22.79 M undefined-22.71 M undefined
20170 undefined-11.15 M undefined-11.05 M undefined

IGM Biosciences stock margins

The IGM Biosciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of IGM Biosciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for IGM Biosciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the IGM Biosciences's sales revenue. A higher gross margin percentage indicates that the IGM Biosciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the IGM Biosciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the IGM Biosciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the IGM Biosciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the IGM Biosciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the IGM Biosciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

IGM Biosciences Margin History

IGM Biosciences Gross marginIGM Biosciences Profit marginIGM Biosciences EBIT marginIGM Biosciences Profit margin
2029e0 %0 %-17.88 %
2028e0 %-11.66 %-44.56 %
2027e0 %-59.62 %-71.91 %
2026e0 %-470.86 %-317.8 %
2025e0 %-2,266.59 %-1,792.31 %
2024e0 %-397.7 %-354.1 %
20230 %-12,369.06 %-11,568.83 %
20220 %-21,304.67 %-20,663.55 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

IGM Biosciences Aktienanalyse

What does IGM Biosciences do?

IGM Biosciences Inc was founded in 2010 in Mountain View, California. It is a biopharmaceutical company focused on the development and commercialization of immunotherapy products for the treatment of cancer. Their business model is based on the use of proprietary technology platform to produce high-quality and high-quantity antibody products. The company has different business areas including research and development, antibody production and testing, and marketing and distribution of their products. They offer a wide range of products such as monoclonal antibodies, multi-specific antibodies, and antibody constructs. Their history began with the development of their platform technology, which allows for the production of antibodies with modified properties. This has led to breakthrough products for the treatment of cancer. One of their main products is IGM-2323, a multi-specific antibody targeting solid tumors. It works by binding to two different targets on the cancer cell simultaneously and activating the immune system to destroy the cancer cell. Another important product is IGM-8444, an antibody construct targeting B-cell lymphomas. It has been designed to enhance the immune response to cancer cells by specifically binding to a surface protein on the cancer cells. IGM Biosciences Inc has also formed partnerships with other companies to collaborate on the development of new products. For example, they have partnered with GlaxoSmithKline (GSK) to develop a new class of multi-specific antibodies for the treatment of cancer. Overall, IGM Biosciences Inc has a strong track record and continues to have significant growth potential in the future. Their business model is based on leveraging their proprietary technology platform to develop innovative immunotherapy products for cancer. With a wide range of products and partnerships in the pipeline, it is likely that this company will continue to be successful in the future. IGM Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding IGM Biosciences's Profit Margins

The profit margins of IGM Biosciences represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of IGM Biosciences's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating IGM Biosciences's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

IGM Biosciences's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When IGM Biosciences’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about IGM Biosciences stock

How much profit has IGM Biosciences made this year?

IGM Biosciences has made -165.37 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -32.89% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does IGM Biosciences publish its earnings?

IGM Biosciences publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of IGM Biosciences?

The profits of IGM Biosciences are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of IGM Biosciences?

You can learn more about the earnings of IGM Biosciences by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does IGM Biosciences pay?

Over the past 12 months, IGM Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGM Biosciences is expected to pay a dividend of 0 USD.

What is the dividend yield of IGM Biosciences?

The current dividend yield of IGM Biosciences is .

When does IGM Biosciences pay dividends?

IGM Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of IGM Biosciences?

IGM Biosciences paid dividends every year for the past 0 years.

What is the dividend of IGM Biosciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is IGM Biosciences located?

IGM Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of IGM Biosciences from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did IGM Biosciences pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of IGM Biosciences in the year 2023?

In the year 2023, IGM Biosciences distributed 0 USD as dividends.

In which currency does IGM Biosciences pay out the dividend?

The dividends of IGM Biosciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von IGM Biosciences

Our stock analysis for IGM Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGM Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.